click below
click below
Normal Size Small Size show me how
Mod 4 PT Final
| Question | Answer |
|---|---|
| A tablet that releases one dose immediately and then releases a second dose sometime later is a ---- tablet. | modified release |
| Drugs can pass through biological membranes | Through aqueous pores, by active transport, and by passive diffusion (all of the above) |
| Extended agonist stimulation leads to a | Decrease number of receptors |
| Bioequivalency is determined by comparing the ---- two products | bioavailabilities |
| In the blood concentration-time profile, the duration of action can be measured as the | time from when blood concentrations first reaches the MEC to when the declining blood concentrations reaches then falls below the MEC |
| Levofloxacin has been shown to bind to calcium, magnesium, and aluminum ions and decrease the bioavailability of levofloxacin. What type of drug-drug interaction is this? | complex formation |
| What criteria should not be used to determine drug dosages for infants? | age alone |
| Which is not a mechanism of drug action? | changes in metabolism, chemical reaction, and protective/physical. (all of the above) |
| Interactions that alter drug absorption can be minimized by separating the administration of the drug and food intake by: | 2 hours |
| Which route of administration does not have an absorption step? | intravenous |
| When a drug is displaced from serum protein by a stronger binding drug the amount of drug A will | increase the amount of free drug A |
| The ---- is the blood concentration needed to produce a response. | Minimum effective concentration (MEC) |
| As blood concentrations fall in a blood concentration-time profile ---- is the predominant process | distribution and metabolism |
| Extended antagonist stimulation leads to a | increased number of receptors |
| When drug molecules are bound to plasma or tissue proteins they are | inactive |
| Pharmaceutical alternatives have the | same active ingredient, different salt form of the active ingredient and different dosage forms. (all of the above) |
| Drugs bind to many proteins, plasma proteins | drug remains biologically inactive |
| Elderly patients may experience more drug interactions than other populations because | all of the above |
| Which is not a means of losing orally administered drug? | administer a solution |
| most drugs given orally are absorbed into the blood from the | small intestine |
| The percentage or fraction of an administered dose of a drug that actually reaches the systemic circulation and the rate at which this occurs is the drug's | bioavailability |
| To avoid first-pass metabolism, administer the drug | by a parenteral route |
| ---- occurs when two drugs with similar pharmacological actions result in effect equal to the sum of their individual affects. | additive effect |
| most drugs given orally are absorbed into the blood from the | small intestine |
| Glomerular filtration is the blood filter process of the | kidney |
| What would not be responsible for increased drug bioavailibility in hepatic disease? | increased first pass effect |
| in metabolism, the breakdown of drugs into metabolites is caused by | enzymes |
| When a drug binds to a receptor and affects the normal cellular process, it is an | agonist |
| the place where a drug causes an effect to occur is | site of action |
| which set of circumstances will result in a drug undergoing urinary excretion but not urinary re-absorption? | basic drug in low pH urine |
| which physiological change occurs during pregnancy? | decreased gastric emptying |
| First-pass metabolism refers to the substantial degradation of the drug caused by enzyme metabolism in the | liver |
| Bioavailability measures | rate and extent the drug is available to the site of action |
| most drugs and their metabolites are excreted by the | kidneys |
| what does first pass metabolism have on drug absorption? | decrease absorption |
| Which is generally a characteristic of a Type A ADR | dose-dependent |
| Spinach and other green vegetables contain vitamin ---- that inhibits the action of oral anticoagulants | K |
| Tissue protein | acts as a depot for the drug |